{"id":2417,"date":"2017-03-07T14:31:00","date_gmt":"2017-03-07T14:31:00","guid":{"rendered":"https:\/\/world-heart-federation.org\/news\/acc-65th-annual-scientific-sessions-chicago-2-4-april\/"},"modified":"2021-04-30T19:10:19","modified_gmt":"2021-04-30T18:10:19","slug":"acc-65th-annual-scientific-sessions-chicago-2-4-april","status":"publish","type":"news","link":"https:\/\/world-heart-federation.org\/news\/acc-65th-annual-scientific-sessions-chicago-2-4-april\/","title":{"rendered":"ACC 65th Annual Scientific Sessions, Chicago, 2-4 April"},"content":{"rendered":"
World Health Day 2016 takes place on 7 April with a focus on beating diabetes<\/p>\n<\/div>\n
Every year, the World Health Organization (WHO) selects a priority area of global public health concern as the theme for World Health Day. The theme for World Health Day 2016 will be diabetes, a non-communicable disease (NCD) that is a risk factor for cardiovascular disease (CVD) and has a direct impact on 415 million people globally.<\/p>\n<\/div>\n
World Heart Federation President Salim Yusuf presents Hope-3 trials in Chicago<\/p>\n<\/div>\n
The research team from the Population Health Research Institute (PHRI) of McMaster University and Hamilton Health Sciences have identified three simple methods to prevent heart attacks and stroke, in a study of more than 12,000 patients from 21 countries.<\/p>\n<\/div>\n
\u201cThese are incredibly important findings with potential for significant global impact,\u201d said Dr. Salim Yusuf, principal investigator and executive director of PHRI. \u201cIf just 10 percent of the world\u2019s population at intermediate risk of CVD [cardiovascular disease] is impacted, we\u2019re talking about 20 to 30 million people who could be helped by these drugs.\u201d<\/p>\n<\/div>\n
Three studies on the methods have been published today in the New England Journal of Medicine. Under the name of HOPE-3, or Heart Outcomes Prevention Evaluation-3, the studies involved 228 centres looking at the effects of the three treatments in people at intermediate risk of, but without, clinical heart disease.<\/p>\n<\/div>\n
The Hope-3 trials are being presented at the 2016 American College of Cardiology (ACC) Scientific Session and Expo in Chicago this weekend by the research leaders: Dr. Salim Yusuf and Dr. Eva Lonn, both professors of medicine of McMaster\u2019s Michael G. DeGroote School of Medicine, and Jackie Bosch, an associate professor of the university\u2019s School of Rehabilitation Science.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Attended by cardiovascular professionals from around the world, the American College of Cardiology’s (ACC) 65th Sienctific Sessions and Expo promises to be an exciting opportunity for learning, sharing and networking. Come and visit the World Heart Federation at booth 3082. World Health Day 2016 takes place on 7 April with a focus on beating diabetes […]<\/p>\n","protected":false},"featured_media":2418,"template":"","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"event":[],"project-campaign":[],"topic":[],"class_list":["post-2417","news","type-news","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n